Peptide Comparisons: Head-to-Head Analysis & Decision Guides
Side-by-side peptide analysis to help you understand the differences. Every comparison backed by clinical data, real-world reports, and transparent methodology.
Key Takeaway
This guide covers everything you need to know about peptide comparisons. Scroll to any section using the table of contents, or browse related articles at the bottom.
Peptide Comparisons: How to Compare Peptides for Weight Loss, Healing, and Performance
The peptide landscape has expanded rapidly. Dozens of compounds are now available through prescriptions, compounding pharmacies, and research chemical suppliers. Some are FDA-approved. Most are not. Some have robust clinical trial data. Others rely almost entirely on animal studies and anecdotal reports.
Choosing the right peptide for a specific goal requires comparing them honestly -- weighing efficacy data, side effect profiles, cost, legal status, and quality of evidence. That is what this guide is built to do.
This is not medical advice. The information on this page is for educational and informational purposes only. We are not doctors. Nothing here should be interpreted as a recommendation to use any peptide or medication. Always consult a qualified healthcare provider before starting any peptide protocol. Individual results vary significantly. See our full medical disclaimer.
This pillar page serves as the central hub for all peptide comparisons on peptidenerds.com. We link to detailed head-to-head comparison pages throughout. Start here for the framework, then drill into the specific matchups that matter to you.
Why Comparing Peptides Matters
Not all peptides do the same thing. And peptides that target the same outcome -- like weight loss -- can differ dramatically in how they work, how well they work, and what risks they carry.
Here is the problem: most peptide information online is either marketing copy from vendors trying to sell product, or forum posts from anonymous users sharing unverified personal experiences. Neither gives you a reliable basis for comparison.
We built this resource to fill that gap. Every comparison on this site is structured around the same framework:
- Mechanism of action -- how does each peptide work at the molecular level?
- Efficacy data -- what do clinical trials or preclinical studies actually show?
- Side effect profile -- what are the known and reported adverse effects?
- Cost and access -- what does it actually cost, and how easy is it to obtain?
- Quality of evidence -- are we talking about Phase 3 human trials, animal studies, or forum posts?
That last point is critical. A peptide with strong Phase 3 trial data (like semaglutide) sits on a fundamentally different evidence tier than a peptide with only rodent studies (like BPC-157). Both may be useful. But you should know the difference before making decisions.
Our Comparison Methodology
Every comparison page on this site follows a standardized methodology. Here is how we evaluate peptides:
Evidence Tiers
We classify the strength of evidence for each peptide into four tiers:
Tier 1 -- FDA-approved with Phase 3 data. Large-scale, randomized controlled trials in humans. Published in peer-reviewed journals. Examples: semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound).
Tier 2 -- Phase 2 data or strong observational studies. Moderate-sized human trials with promising but incomplete data. Not yet FDA-approved for the indication being discussed. Example: retatrutide (Phase 2 weight loss data published).
Tier 3 -- Preclinical research only. Animal studies published in peer-reviewed journals, but no completed human clinical trials. Examples: BPC-157, TB-500, AOD-9604 (for most claimed indications).
Tier 4 -- Anecdotal only. No published research supporting the claimed use. Based entirely on user reports from forums, social media, or vendor marketing. We flag these clearly and treat claims with appropriate skepticism.
Data Sources
We pull data from:
- PubMed -- peer-reviewed medical literature
- ClinicalTrials.gov -- registered clinical trial results and ongoing studies
- FDA labeling -- official prescribing information for approved drugs
- Conference presentations -- data presented at medical conferences (ADA, ObesityWeek, ENDO) before full publication
- Community reports -- Reddit, forums, and social media (labeled as anecdotal and never treated as evidence)
What We Do Not Do
- We do not accept paid placements or sponsored comparisons
- We do not rank peptides based on vendor relationships
- We do not present anecdotal reports as equivalent to clinical data
- We do not make therapeutic claims for research-only peptides
GLP-1 Receptor Agonist Comparisons
GLP-1 receptor agonists are the most clinically validated peptide class for weight management. Three compounds dominate the conversation: semaglutide, tirzepatide, and retatrutide. Each represents a different generation of incretin-based therapy.
Semaglutide vs Tirzepatide
This is the most common comparison in the weight loss peptide space. Both are FDA-approved. Both have extensive clinical trial programs. And now we have head-to-head data.
Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut produces after eating. This slows gastric emptying, reduces appetite, and improves insulin sensitivity.
Tirzepatide (brand names: Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates two incretin receptors instead of one. The dual mechanism appears to produce stronger appetite suppression and greater metabolic effects.
The Trial Data
STEP trials (semaglutide):
- STEP 1: 16.9% average body weight loss at 68 weeks (2.4mg dose)
- STEP 3: 16.0% loss with intensive behavioral therapy
- STEP 5: 15.2% loss sustained at 2 years
SURMOUNT trials (tirzepatide):
- SURMOUNT-1: 22.5% average body weight loss at 72 weeks (15mg dose)
- SURMOUNT-2 (participants with T2D): 14.7% loss at 72 weeks
- SURMOUNT-3: 26.6% loss with prior lifestyle intervention run-in
SURMOUNT-5 (head-to-head):
| Metric | Tirzepatide (15mg) | Semaglutide (2.4mg) |
|---|---|---|
| Average weight loss | 20.2% | 13.7% |
| Patients losing 10%+ | 81.5% | 66.1% |
| Patients losing 20%+ | 55.0% | 24.5% |
| Discontinuation (side effects) | 4.3% | 2.9% |
On a population level, tirzepatide produces greater average weight loss. But individual variation is significant. Some people respond better to semaglutide. Some cannot tolerate tirzepatide at higher doses. The "best" option depends on individual response, tolerance, and access.
For the full breakdown, read our detailed comparison: Semaglutide vs Tirzepatide for Weight Loss.
Retatrutide: The Triple Agonist
Retatrutide is a triple agonist -- it activates GLP-1, GIP, and glucagon receptors. It is currently in Phase 2 trials and is not FDA-approved.
Phase 2 data presented at ADA 2023 and published in the New England Journal of Medicine showed:
- 24.2% average body weight loss at 48 weeks (12mg dose)
- Some participants lost over 30% of body weight
- GI side effects were the most common adverse events (consistent with the GLP-1 class)
These are Phase 2 results with a relatively small sample size. Phase 3 trials are ongoing. We will not know the full safety and efficacy picture until those trials report out, likely in 2026 or 2027.
For the latest data: Retatrutide Phase 2 Results.
GLP-1 Comparison Summary Table
| Compound | Receptor Targets | Best Published Weight Loss | FDA Status | Evidence Tier |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 16.9% (STEP 1) | Approved (obesity, T2D) | Tier 1 |
| Tirzepatide | GLP-1 + GIP | 22.5% (SURMOUNT-1) | Approved (obesity, T2D) | Tier 1 |
| Retatrutide | GLP-1 + GIP + Glucagon | 24.2% (Phase 2) | Not approved | Tier 2 |
How to Compare FDA-Approved vs Research Peptides
This distinction is fundamental, and it is often glossed over in online peptide discussions. Here is how we think about it.
FDA-Approved Peptides
These have gone through the full regulatory process: preclinical testing, Phase 1 (safety), Phase 2 (dosing and efficacy), Phase 3 (large-scale efficacy and safety), and FDA review. They have official prescribing information, known side effect profiles from thousands of patients, and post-market surveillance.
Examples: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda).
When comparing FDA-approved peptides, we have high-quality data. We can cite specific trial results, adverse event rates, and long-term safety data. The comparisons are robust.
Research Peptides
These have not completed the FDA approval process. Evidence ranges from promising preclinical data to almost no published research at all. They are legally sold as "research chemicals" and are not approved for human use.
Examples: BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Tesamorelin (approved for HIV lipodystrophy only, not general use).
When comparing research peptides, we are working with weaker evidence. We say so clearly. Animal study results do not always translate to humans. Anecdotal reports carry inherent bias. Dosing protocols from forums are not validated by controlled research.
The Comparison Trap
The biggest mistake in peptide comparison content is treating FDA-approved drugs and research peptides as if they sit on equal footing. They do not.
When someone asks "Is AOD-9604 better than semaglutide for weight loss?" the honest answer is: we do not have the data to make that comparison reliably. Semaglutide has Phase 3 trials with thousands of participants. AOD-9604 has limited human data and failed to show significant weight loss in its most notable clinical trial.
We cover this comparison in detail here: AOD-9604 vs Semaglutide.
Brand Name vs Compounded Peptides
This is one of the most practical comparison questions people have, and it is entirely about access, cost, and risk -- not efficacy.
Ozempic vs Wegovy
Both contain semaglutide. Both are manufactured by Novo Nordisk. The difference is the indication and dosing:
- Ozempic is FDA-approved for type 2 diabetes. Maximum dose: 2.0mg weekly.
- Wegovy is FDA-approved for weight management. Maximum dose: 2.4mg weekly.
The compound is identical. The formulation is identical. The difference is regulatory labeling and the dose titration schedule. Many people use Ozempic off-label for weight loss because insurance coverage for Wegovy has historically been more limited.
Full comparison: Ozempic vs Wegovy.
Mounjaro vs Zepbound
Same dynamic, different manufacturer (Eli Lilly):
- Mounjaro is FDA-approved for type 2 diabetes.
- Zepbound is FDA-approved for weight management.
Both contain tirzepatide. Same compound, same manufacturing, different regulatory label.
Full comparison: Mounjaro vs Zepbound.
Compounded Semaglutide and Tirzepatide
Compounding pharmacies produce custom formulations of these peptides, typically at lower cost than brand-name versions. This became widespread during the FDA-declared shortage of semaglutide and tirzepatide.
Key considerations when comparing compounded vs brand-name:
- Potency verification -- compounded peptides may not undergo the same quality testing as brand-name drugs. Third-party testing results vary.
- Sterility -- compounding pharmacies are regulated by state boards of pharmacy, not the FDA. Quality standards can differ.
- Cost -- compounded versions are typically 50-80% cheaper than brand-name. This is the primary driver of demand.
- Legal status -- the FDA's position on compounded versions of commercially available drugs has been contested in court. The regulatory landscape is shifting. Check current FDA guidance before sourcing compounded versions.
This is not a quality comparison we can make with data. It is a risk-access-cost tradeoff that each person evaluates with their healthcare provider.
Cost Comparison Considerations
Peptide costs vary dramatically based on source, insurance status, and whether you are using brand-name or compounded versions.
Brand-Name GLP-1 Costs (Without Insurance)
| Peptide | Monthly Cost (Approx.) | Notes |
|---|---|---|
| Ozempic (semaglutide) | $900-1,100 | Diabetes indication |
| Wegovy (semaglutide) | $1,300-1,500 | Weight management indication |
| Mounjaro (tirzepatide) | $1,000-1,200 | Diabetes indication |
| Zepbound (tirzepatide) | $1,000-1,200 | Weight management indication |
Insurance, manufacturer coupons, and savings programs can reduce these costs significantly. Coverage varies by plan, employer, and state.
Compounded GLP-1 Costs
Compounded semaglutide and tirzepatide typically run $150-400 per month, depending on the pharmacy, dose, and formulation. Telehealth platforms that bundle prescriptions with compounded peptides range from $200-600 per month all-in.
Research Peptide Costs
Research peptides like BPC-157, TB-500, CJC-1295, and Ipamorelin typically cost $30-100 per vial from research chemical suppliers. Monthly costs for a standard protocol usually fall in the $50-200 range depending on the compound, dose, and source.
These are not prescription costs. Research peptides are sold as research chemicals, not medications. Quality control, purity, and sterility vary widely by supplier.
The Real Cost Question
The most useful cost comparison is not just sticker price. It is cost per unit of outcome, adjusted for quality of evidence and risk:
- A $1,200/month FDA-approved drug with Phase 3 data, quality manufacturing, and physician oversight is a different value proposition than a $60/month research peptide with animal-study-only evidence and no quality guarantees.
- That does not mean the expensive option is always better. But cost should be evaluated in context, not in isolation.
Side Effect Comparison Framework
Side effects are one of the most important comparison dimensions. Here is how we structure side effect comparisons across the site.
GLP-1 Receptor Agonist Side Effects
The GLP-1 class shares a common side effect profile. The most frequent adverse events are gastrointestinal:
- Nausea -- the most common side effect for both semaglutide and tirzepatide. Usually dose-dependent and improves over weeks. Tirzepatide Nausea: How Long Does It Last?
- Vomiting -- less common than nausea, but reported in 5-15% of clinical trial participants at higher doses.
- Diarrhea or constipation -- GI motility changes are expected with GLP-1 activation.
- Injection site reactions -- mild redness, swelling, or itching at the injection site.
Less common but more serious reported events:
- Pancreatitis -- rare but reported. Both semaglutide and tirzepatide carry label warnings.
- Gallbladder events -- cholelithiasis (gallstones) reported at higher rates in trials vs placebo.
- Thyroid C-cell concerns -- see the Cancer Risk section below and our deep dive on Peptides and Thyroid Problems.
For a full side effect overview, see: GLP-1 Side Effects: What to Expect and Semaglutide Side Effects Long-Term.
Healing Peptide Side Effects
BPC-157 and TB-500 have limited published human safety data. Most of what we know comes from animal studies and user reports:
- BPC-157 -- generally reported as well-tolerated in animal studies. User reports occasionally mention mild nausea, dizziness, or headache. No systematic human safety data exists.
- TB-500 -- similar profile. User reports include occasional fatigue, headache, and injection site irritation. Again, no controlled human safety data.
The absence of reported side effects is not the same as proven safety. It means the research has not been done.
Comparing Side Effects Across Classes
When comparing side effects between different peptide classes (for example, GLP-1s vs growth hormone peptides), we use the following framework:
- Incidence rate -- how often does the side effect occur? (Clinical trial data when available)
- Severity -- is it mild and transient, or serious and potentially dangerous?
- Dose-dependence -- does the side effect scale with dose? Can it be managed by adjusting dosage?
- Reversibility -- does the side effect resolve when the peptide is discontinued?
- Data quality -- is the side effect data from Phase 3 trials, case reports, or forum posts?
Healing Peptide Comparisons
BPC-157 vs TB-500
These are the two most widely discussed healing peptides. Both are research compounds with no FDA approval for human use. Both are studied for tissue repair properties. But they work through different mechanisms and show different strengths.
BPC-157 works primarily through the nitric oxide system and angiogenesis. It has the strongest preclinical evidence for gut healing, tendon repair, and localized tissue injuries.
TB-500 (Thymosin Beta-4) works through actin regulation and cell migration. It shows broader systemic effects in preclinical research, including cardiac tissue repair and systemic inflammation reduction.
Key differences:
| Factor | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Nitric oxide, angiogenesis | Actin regulation, cell migration |
| Best evidence for | Gut healing, tendons | Cardiac repair, systemic inflammation |
| Administration | Oral and injection (oral bioavailability debated) | Injection (subcutaneous or intramuscular) |
| Human clinical data | Very limited | Very limited |
| Common stacking | Often paired with TB-500 | Often paired with BPC-157 |
Many users report stacking both peptides together for injury recovery. Anecdotal reports suggest the combination may produce faster healing than either alone, though no controlled studies have tested this.
For the full comparison: BPC-157 vs TB-500: Which Healing Peptide Should You Use?.
Also see our dedicated comparison pages: BPC-157 vs TB-500.
Growth Hormone Peptide Comparisons
Growth hormone secretagogues (GHS) are peptides that stimulate the body's natural growth hormone production. Unlike direct GH injection (exogenous HGH), these peptides work by signaling the pituitary gland to release more of its own growth hormone.
The most commonly discussed GHS peptides include:
CJC-1295 + Ipamorelin
This is the most popular GHS stack. CJC-1295 is a growth hormone releasing hormone (GHRH) analog. Ipamorelin is a growth hormone releasing peptide (GHRP) that acts as a ghrelin mimetic.
They work through complementary mechanisms:
- CJC-1295 amplifies the GH release signal (like turning up the volume)
- Ipamorelin triggers the GH release pulse (like pressing the button)
Together, they produce a stronger GH pulse than either alone. This is the theoretical basis for the stack, supported by the known pharmacology of GHRH and GHRP pathways.
Published data on this specific combination in healthy adults is limited. Most evidence comes from the individual compounds studied separately, plus clinical use in anti-aging and sports medicine practices.
For more detail: CJC-1295 + Ipamorelin Weight Loss Results.
GHS vs GLP-1 Comparisons
People sometimes ask whether growth hormone peptides can substitute for GLP-1 agonists for weight loss. The short answer: no, not based on current evidence. GLP-1 receptor agonists produce significantly greater and more consistent weight loss in clinical trials than anything reported for GHS peptides.
Growth hormone peptides may support body composition improvements (reduced fat mass, preserved lean mass) through their effects on growth hormone and IGF-1. But the magnitude of weight loss is not comparable to semaglutide or tirzepatide.
These are different tools for different goals. Comparing them head-to-head on weight loss alone misrepresents what GHS peptides are typically used for.
Oral vs Injectable Comparisons
Route of administration is a practical comparison factor that matters to many people.
Oral Semaglutide vs Injectable Semaglutide
Semaglutide is available in both oral (Rybelsus) and injectable (Ozempic, Wegovy) forms. This makes it unique among GLP-1 agonists.
Key differences:
| Factor | Oral (Rybelsus) | Injectable (Ozempic/Wegovy) |
|---|---|---|
| Dosing | Daily | Weekly |
| Max approved dose | 14mg (diabetes) | 2.0mg (Ozempic) / 2.4mg (Wegovy) |
| Bioavailability | ~1% (requires fasting) | ~89% (subcutaneous) |
| Weight loss data | Modest in PIONEER trials | Stronger in STEP trials |
| Convenience | No injections | Once weekly injection |
| Restrictions | Must take on empty stomach, 30 min before food/water | Inject any time |
The injectable form has demonstrated greater weight loss in published trials. The oral form is currently approved only for diabetes (as Rybelsus), though higher oral doses are being studied for weight management.
For the full comparison: Oral Semaglutide vs Injectable for Weight Loss.
Also see: Oral Semaglutide vs Injectable.
How to Use Our Comparison Tools
We have built several resources to help you compare peptides systematically:
Head-to-Head Comparison Pages
Each comparison page follows the same structure:
- Mechanism of action for both peptides
- Side-by-side efficacy data (with evidence tier noted)
- Side effect comparison
- Cost comparison
- Who each peptide might be better suited for
- Sources and citations
Browse all comparisons:
- Semaglutide vs Tirzepatide
- BPC-157 vs TB-500
- Ozempic vs Wegovy
- Mounjaro vs Zepbound
- Oral Semaglutide vs Injectable
Individual Peptide Pages
Each peptide on the site has a dedicated page covering its mechanism, research, dosing protocols (as reported in literature), side effects, and legal status. These pages give you the full picture on a single compound before you start comparing.
Blog Deep Dives
Our blog posts cover specific comparison angles in more detail than the structured comparison pages. These are useful when you want context, analysis, and discussion -- not just data tables.
Key comparison articles:
- Semaglutide vs Tirzepatide for Weight Loss
- AOD-9604 vs Semaglutide
- BPC-157 vs TB-500: Which Healing Peptide Is Better?
- Oral Semaglutide vs Injectable for Weight Loss
What Good Comparison Research Looks Like
If you are evaluating peptides on your own, here are the principles we use and recommend:
Check the evidence tier first. Before comparing outcomes, ask: what quality of evidence supports each claim? A Phase 3 RCT result and a Reddit post are not equivalent data points.
Look at the study population. Trial results in people with type 2 diabetes may not translate directly to people without diabetes. Results in obese populations may differ from people closer to normal weight. Context matters.
Watch for cherry-picked data. Some sources cite only the most favorable study or the highest-responding subgroup. Look at the full trial program, not just the best headline number.
Understand what "statistically significant" means. A statistically significant difference may or may not be clinically meaningful. A 1% difference in weight loss can be statistically significant in a large trial without being practically relevant to an individual.
Separate mechanism from outcome. A peptide can have a theoretically sound mechanism of action and still fail to produce meaningful results in humans. Mechanism matters, but outcomes matter more.
Frequently Asked Questions
What is the most effective peptide for weight loss?
Based on published clinical trial data, tirzepatide (Zepbound/Mounjaro) has produced the highest average weight loss among FDA-approved options -- up to 22.5% body weight reduction in the SURMOUNT-1 trial. Retatrutide showed even higher numbers in Phase 2 (24.2%), but it is not yet approved and Phase 3 data is pending. "Most effective" also depends on individual response, tolerance, and access. Some people respond better to semaglutide than tirzepatide, despite the population averages.
Is tirzepatide better than semaglutide?
On average, yes -- for weight loss. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide at 72 weeks. But averages do not predict individual results. Some people experience more side effects on tirzepatide and tolerate semaglutide better. The "better" option is the one that works for you with manageable side effects. Read the full comparison: Semaglutide vs Tirzepatide.
Can you compare FDA-approved peptides with research peptides?
You can, but you need to acknowledge the evidence gap. FDA-approved peptides like semaglutide have data from thousands of participants in controlled trials. Research peptides like BPC-157 or AOD-9604 have mostly animal data and anecdotal reports. Comparing them on efficacy is not apples-to-apples. We always note the evidence tier when making these comparisons.
Is compounded semaglutide the same as Ozempic or Wegovy?
The active compound is the same molecule -- semaglutide. But the manufacturing process, quality controls, and regulatory oversight are different. Brand-name semaglutide from Novo Nordisk undergoes FDA-regulated manufacturing. Compounded semaglutide is produced by compounding pharmacies regulated at the state level. Potency and sterility may vary. This is a quality assurance question, not a chemistry question.
What is the cheapest GLP-1 peptide?
Compounded semaglutide is typically the lowest-cost GLP-1 option, ranging from $150-400 per month depending on the pharmacy and dose. Brand-name options without insurance run $900-1,500 per month. With insurance coverage or manufacturer savings programs, brand-name costs can drop significantly. The cheapest option is not automatically the best value -- factor in quality assurance, physician oversight, and the overall cost of your healthcare.
Is BPC-157 or TB-500 better for injuries?
It depends on the type of injury. Based on preclinical research, BPC-157 shows stronger evidence for gut healing and tendon injuries (localized, nitric oxide-driven repair). TB-500 shows more promise for systemic injuries, cardiac tissue, and broad anti-inflammatory effects (actin-mediated cell migration). Many users stack both. Neither is FDA-approved for injury treatment. See the full comparison: BPC-157 vs TB-500.
How do growth hormone peptides compare to GLP-1s for weight loss?
They are not comparable for weight loss based on current evidence. GLP-1 agonists (semaglutide, tirzepatide) produce 15-22% body weight loss in clinical trials. Growth hormone secretagogues (CJC-1295, Ipamorelin) are primarily used for body composition, recovery, and anti-aging -- not as primary weight loss agents. If your goal is significant weight loss, GLP-1 agonists have far stronger data.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide made by the same manufacturer (Novo Nordisk). Ozempic is approved for type 2 diabetes (max dose 2.0mg). Wegovy is approved for weight management (max dose 2.4mg). The molecule is identical. The difference is the FDA-approved indication, the dose titration schedule, and insurance coverage. See: Ozempic vs Wegovy.
Should I take oral or injectable semaglutide?
Injectable semaglutide has demonstrated greater weight loss in clinical trials and has higher bioavailability (~89% vs ~1% for oral). Oral semaglutide (Rybelsus) must be taken daily on an empty stomach with specific timing restrictions. Injectable semaglutide (Ozempic/Wegovy) is taken once weekly with no food restrictions. If weight loss is the primary goal and you are comfortable with weekly injections, the injectable form has stronger published data. See: Oral Semaglutide vs Injectable.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. See our full medical disclaimer.
Sources
- STEP 1 Trial -- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021.
- SURMOUNT-1 Trial -- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 2022.
- SURMOUNT-5 Trial -- Tirzepatide vs Semaglutide head-to-head comparison. NEJM, 2024.
- Retatrutide Phase 2 -- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM, 2023.
- BPC-157 review -- Seiwerth S, et al. "BPC 157 and Standard Angiogenic Growth Factors." Current Pharmaceutical Design, 2018. PMID: 29898181.
- Thymosin Beta-4 review -- Goldstein AL, et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 2005.
- PIONEER trial program (oral semaglutide) -- Multiple publications, 2019-2021.
- FDA prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound.
Related Articles
Deep dives and guides in this topic area.
Related Compounds
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has demonstrated significant weight loss effects in clinical trials. Sold under the brand names Ozempic (diabetes) and Wegovy (weight management), it is the most prescribed anti-obesity medication worldwide as of 2026. Semaglutide works by mimicking the incretin hormone GLP-1, reducing appetite, slowing gastric emptying, and improving insulin sensitivity. The STEP clinical trial program — spanning over 10,000 participants across multiple studies — established semaglutide as a breakthrough treatment for obesity, with average weight loss of 14.9% over 68 weeks. An oral formulation (Rybelsus for diabetes, oral Wegovy for weight loss) expanded access beyond injection-only delivery. Semaglutide also demonstrated cardiovascular benefits in the SELECT trial, reducing major adverse cardiovascular events by 20% in overweight adults.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated greater weight loss than any other approved anti-obesity medication. Sold as Mounjaro (diabetes) and Zepbound (weight management), it activates two complementary incretin pathways simultaneously. The SURMOUNT clinical trial program showed average weight loss of 20.9% at the highest dose — with over half of participants losing 20%+ of body weight. In the landmark SURMOUNT-5 head-to-head trial against semaglutide, tirzepatide produced statistically superior weight loss (20.2% vs 13.7%). Developed by Eli Lilly, tirzepatide represents a paradigm shift from single-receptor to multi-receptor approaches in obesity treatment.
Retatrutide
Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly that simultaneously activates three metabolic pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. No other obesity medication in clinical development targets all three receptors in a single molecule. The compound emerged from Eli Lilly's incretin research program, with Phase 1b results published in The Lancet in 2022 (PMID: 36354040) demonstrating approximately 9 kg of body weight reduction in just 12 weeks — enough to advance rapidly into Phase 2. The Phase 2 obesity trial, published in the New England Journal of Medicine in 2023 (PMID: 37366315), produced what was then the highest weight loss ever reported for any pharmaceutical agent: 24.2% body weight reduction over 48 weeks at the 12 mg dose. Every participant in the highest dose group lost at least 5% of their body weight, and 83% lost at least 15%. A parallel Phase 2 trial in patients with type 2 diabetes, published in The Lancet in 2023 (PMID: 37385280), demonstrated dual metabolic benefits: up to 16.9% weight loss alongside a 2.02% reduction in HbA1c at 36 weeks. A dedicated liver fat substudy, published in Nature Medicine in 2024 (PMID: 38858523), showed near-complete resolution of hepatic steatosis — 86% relative reduction in liver fat at the highest dose, with 86% of participants dropping below the 5% threshold that defines normal liver fat content. Retatrutide entered Phase 3 in 2023 through the TRIUMPH clinical trial program — a novel basket trial structure testing the compound simultaneously for obesity, obstructive sleep apnea, and knee osteoarthritis across four major studies enrolling over 5,800 participants (PMID: 41090431). The first Phase 3 readout came in December 2025 from TRIUMPH-4, which tested retatrutide specifically in adults with obesity and knee osteoarthritis. Topline results showed 28.7% average body weight loss at 68 weeks (26.6% placebo-adjusted, approximately 71.2 pounds) at the 12 mg dose — peer-reviewed publication pending. The trial also demonstrated a 75.8% reduction in knee osteoarthritis pain scores, with one in eight participants becoming completely free of knee pain. However, TRIUMPH-4 also revealed a new safety signal not seen in Phase 2: dysesthesia (abnormal sensations of touch), occurring in 8.8% of participants at 9 mg and 20.9% at 12 mg versus 0.7% on placebo. While generally mild and infrequently leading to discontinuation, this finding is being closely monitored in subsequent TRIUMPH readouts. Seven additional Phase 3 readouts are expected throughout 2026, including data on obstructive sleep apnea and cardiovascular disease populations. If results remain positive, Eli Lilly is projected to submit a New Drug Application to the FDA in late 2026, with potential approval in the first half of 2027. Retatrutide is not currently available by prescription, through compounding pharmacies, or from research peptide vendors — the FDA has explicitly stated it cannot be legally compounded.
BPC-157
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.
TB-500
TB-500
TB-500 is a synthetic version of Thymosin Beta-4 (Tb4), a naturally occurring 43-amino-acid protein that constitutes 70-80% of all beta-thymosins in the human body (PMID: 36464872). While the name "TB-500" is sometimes described as a fragment, most commercial TB-500 products contain the full 43-amino-acid Thymosin Beta-4 sequence. The key active region is the actin-binding domain (amino acids 17-23, the sequence LKKTETQ), which is responsible for promoting cell migration, angiogenesis, and tissue repair — the properties that have driven research interest since the early 2000s. Thymosin Beta-4 was originally isolated from the thymus gland in 1981 and initially studied for its role in immune function. Researchers later discovered broader tissue repair properties, leading to the foundational dermal wound study (PMID: 12581423) which demonstrated accelerated wound closure through enhanced cell migration, collagen deposition, and new blood vessel formation in animal models. This established the mechanistic rationale for all subsequent TB-500 research. The only published human clinical trials for Thymosin Beta-4 are in ophthalmology. RegeneRx Biopharmaceuticals developed RGN-259, a topical eye drop formulation containing 0.1% Thymosin Beta-4, which completed two Phase 2 randomized controlled trials for dry eye disease. The first trial in severe dry eye patients including those with graft-versus-host disease showed a 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining versus placebo (PMID: 25826322). A second trial in 72 subjects showed a 27% reduction in discomfort scores described as safe and well tolerated (PMID: 26056426). Note: primary endpoints in the second trial did not reach significance, though secondary endpoints showed improvement. Effects from the first trial persisted 28 days after treatment ended. Three subsequent Phase 3 dry eye trials (ARISE-1, -2, -3) did not meet their pre-specified co-primary endpoints, though secondary endpoints showed some statistical significance in pooled analyses. Cardiac repair represents the most researched preclinical application. Multiple animal studies demonstrate that Thymosin Beta-4 protects cardiac tissue after myocardial infarction by reducing oxidative damage, inhibiting fibrosis, and promoting new blood vessel formation (PMID: 35712678, 34335970). RegeneRx developed a clinical program for acute myocardial infarction treatment and completed Phase 1 safety protocols, but Phase 2 cardiac trial results were never published and the program appears to have stalled. Hair growth is another well-researched preclinical area. Mouse studies show that Thymosin Beta-4 overexpression leads to faster hair re-growth, higher hair shaft counts, and follicle clustering through P38/ERK/AKT/VEGF signaling pathways (PMID: 26083021). A 2021 review confirmed that exogenous Tb4 accelerates hair follicle cycle transitions and promotes migration of hair follicle stem cells (PMID: 33393222). No human hair growth trials have been published. A 2024 pharmacokinetic study introduced a finding that may reframe understanding of how TB-500 works: the metabolite Ac-LKKTE — not the parent TB-500 molecule — showed significant wound repair activity in vitro (PMID: 38382158). This suggests TB-500's reported effects in earlier studies may have been driven by its metabolic breakdown products rather than the intact peptide. Thymosin Beta-4 also demonstrates potent anti-fibrotic properties. It prevents fibrosis across multiple organ systems in animal models, and its N-terminal fragment Ac-SDKP can not only prevent but reverse established fibrosis in liver, lung, heart, and kidney tissue (PMID: 36580759). TB-500 is not FDA-approved for any indication. The FDA classified it as a Category 2 compound, restricting it from compounding pharmacy preparation. In February 2026, the Department of Health and Human Services announced plans to potentially reclassify certain peptides including Thymosin Beta-4, which could affect future regulatory accessibility. TB-500 is prohibited by the World Anti-Doping Agency (WADA) at all times as a Non-Specified Substance under category S2 (Peptide Hormones, Growth Factors, and Related Substances), with first-offense violations carrying a four-year ban. The U.S. Department of Defense has adopted WADA categories, making TB-500 prohibited for all military personnel. Despite its research-only status, TB-500 has been widely used in veterinary medicine, particularly in equine practice for soft tissue injuries — one of the earliest real-world applications that drove interest in human research. The combination of TB-500 with BPC-157, commonly called the "Wolverine Stack" in peptide communities, is one of the most discussed recovery-focused protocols, though no published studies have tested this combination in humans or animals.
Head-to-Head Comparisons
Related Goals
Frequently Asked Questions
Clinical trial data suggests tirzepatide produces greater average weight loss (up to 22.5% in SURMOUNT-1) compared to semaglutide (up to 16.9% in STEP 1). Tirzepatide is a dual GIP/GLP-1 agonist while semaglutide targets GLP-1 only. Individual responses vary. See our detailed semaglutide vs tirzepatide comparison.
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
This content is for educational and informational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol. See our full medical disclaimer.